Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0052 in Patients With Advanced Solid Tumors

NCT06992687 is registered in ClinicalTrials.gov with Shanghai Huaota Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06992687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06992687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0052 in Patients With Advanced Solid Tumors
Lead sponsor
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase
Phase 1/2
Overall status
Enrolling by invitation
Start date
September 1, 2024
Completion date
November 30, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors